Nuvalent, Inc. (NASDAQ: NUVL) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
| Index | - | P/E | - | EPS (ttm) | - | Insider Own | 14.41% | Shs Outstand | 73.69M | Perf Week | 0.00% |
| Market Cap | 9.13B | Forward P/E | - | EPS next Y | -4.35 | Insider Trans | -3.22% | Shs Float | 49.11M | Perf Month | 0.43% |
| Enterprise Value | 9.13B | PEG | - | EPS next Q | - | Inst Own | - | Short Float | 1.46% | Perf Quarter | 14.52% |
| Income | -425.00M | P/S | 0.00 | EPS this Y | - | Inst Trans | - | Short Ratio | 0.31 | Perf Half Y | 18.90% |
| Sales | 0.00 | P/B | 8.30 | EPS next Y | 22.91% | ROA | -33.81% | Short Interest | 715.80K | Perf YTD | 23.23% |
| Book/sh | -0.42 | P/C | - | EPS next 5Y | - | ROE | -42.78% | 52W High | 123.98 -0.02% | Perf Year | 48.63% |
| Cash/sh | 0.14 | P/FCF | - | EPS past 3/5Y | - | ROIC | -35.11% | 52W Low | 71.13 74.27% | Perf 3Y | 199.13% |
| Dividend Est. | - | EV/EBITDA | - | Sales past 3/5Y | - | Gross Margin | 0.00% | Volatility | 0.00% 0.09% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | 0.00 | EPS Y/Y TTM | -44.78% | Oper. Margin | 0.00% | ATR (14) | 0.94 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 16.14 | Sales Y/Y TTM | - | Profit Margin | 0.00% | RSI (14) | 67.59 | Recom | 2.58 |
| Dividend Gr. 3/5Y | - | Current Ratio | 16.14 | EPS Q/Q | -17.80% | SMA20 | 0.16% | Beta | 0.77 | Target Price | 127.32 |
| Payout | 0.00% | Debt/Eq | 0.00 | Sales Q/Q | - | SMA50 | 8.81% | Rel Volume | 0.00 | Prev Close | 123.96 |
| Employees | 234 | LT Debt/Eq | -0.06 | Earnings | Aug 06 | SMA200 | 18.92% | Avg Volume | 2.24M | Price | 123.96 |
| IPO Date | Jul 29, 2021 | Option/Short | Yes / Yes | EPS/Sales Surpr. | -3.72% - | Net Debt/EBITDA | 0.48 | Volume | 0 | Change | 0.00% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Jun-24-26 | Downgrade | Bernstein | Outperform → Market Perform | $189 → $124 |
| Jun-10-26 | Downgrade | TD Cowen | Buy → Hold | |
| Jun-10-26 | Downgrade | Wedbush | Outperform → Neutral | $124 |
| Jun-10-26 | Downgrade | UBS | Buy → Neutral | $132 → $124 |
| Jun-10-26 | Downgrade | Truist Securities | Buy → Hold | $124 |
| Jun-10-26 | Downgrade | Barclays | Overweight → Equal Weight | $124 |
| Jun-10-26 | Downgrade | Guggenheim | Buy → Neutral | $122 → $124 |
| Jun-09-26 | Reiterated | Robert W. Baird | $123 | |
| Jun-09-26 | Reiterated | Stifel Nicolaus | $135 → $124 | |
| Jun-09-26 | Reiterated | Piper Sandler | Overweight | $128 → $124 |
Nuvalent, Inc. is a clinical-stage biopharmaceutical firm dedicated to pioneering novel therapeutic solutions for individuals battling cancer. The company's pipeline features two prominent drug candidates. One of these is NVL-520, a highly selective ROS1 inhibitor capable of penetrating the brain. This compound is specifically designed to target ROS1 fusions that possess the normal ROS1 kinase domain, and crucially, it retains activity against mutations known to confer resistance to both approved and experimental ROS1 inhibitors. NVL-520 is currently undergoing Phase I clinical evaluation. Nuvalent's second key asset is NVL-655, an ALK-selective inhibitor that also exhibits brain-penetrant properties. This therapy seeks to address significant limitations of earlier generations of ALK inhibitors (first-, second-, and third-generation), including the development of treatment resistance, central nervous system-related adverse effects, and brain metastases. NVL-655 is presently being assessed in Phase I/II clinical trials. The company was established in 2017 and is based in Cambridge, Massachusetts.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Cost of Goods Sold Incl. D&A | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Gross Profit | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Selling, General and Administrative Excl. Other | 107 | 63 | 36 | 22 | 10 | 2 | 1 | |
| Research and Development | 307 | 218 | 113 | 64 | 36 | 15 | 10 | |
| Other Operating Expense | 0 | -1 | 0 | 0 | 0 | 0 | -1 | |
| Operating Income | -414 | -280 | -149 | -86 | -46 | -17 | -10 | |
| Interest Expense | 0 | 0 | 23 | 0 | 0 | 0 | 0 | |
| Unusual Expense | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | -10 | 20 | 47 | 4 | -1 | 2 | -1 | |
| Net Income Before Taxes | -425 | -260 | -126 | -82 | -46 | -15 | -12 | |
| Income Taxes | 1 | 1 | 0 | 0 | 0 | 0 | 0 | |
| Consolidated Net Income | -425 | -261 | -126 | -82 | -46 | -15 | -12 | |
| Net Income From Continuing Operations | -425 | -261 | -126 | -82 | -46 | -15 | -12 | |
| Net Income | -425 | -261 | -126 | -82 | -46 | -15 | -12 | |
| EPS (Recurring) | -5.85 | -3.93 | -2.17 | -1.65 | -2.13 | -0.64 | -0.24 | |
| EPS (Basic, Before Extraordinaries) | -5.85 | -3.93 | -2.17 | -1.65 | -2.13 | -0.64 | -0.24 | |
| EPS (Diluted) | -5.85 | -3.93 | -2.17 | -1.65 | -2.13 | -0.64 | -0.24 | |
| EBITDA | -10 | 20 | -126 | -82 | -46 | -17 | -1 | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | |
| Price To Sales Ratio | — | — | — | — | — | — | — | |
| Gross Margin | — | — | — | — | — | — | — | |
| Operating Margin | — | — | — | — | — | — | — | |
| Net Margin | — | — | — | — | — | — | — | |
| Shares Outstanding | 73 | 66 | 58 | 50 | 22 | 23 | 48 | |
| Market Capitalization | 7,343 | 5,166 | 4,268 | 1,489 | 419 | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Pelish Henry E. | Chief Scientific Officer | Jul 09 '26 | Sale | 123.81 | 2,111 | 261,363 | 63,493 | Jul 10 |
| Porter James Richard | President and CEO | Jul 06 '26 | Sale | 123.72 | 30,000 | 3,711,600 | 324,879 | Jul 08 |
| Porter James Richard | President and CEO | Jul 06 '26 | Option Exercise | 18.93 | 30,000 | 567,900 | 354,879 | Jul 08 |
| Noci Darlene | Chief Development Officer | Jul 01 '26 | Sale | 123.59 | 23,000 | 2,842,570 | 58,117 | Jul 06 |
| Balcom Alexandra | Chief Financial Officer | Jul 01 '26 | Option Exercise | 13.26 | 11,430 | 151,547 | 96,963 | Jul 06 |
| Balcom Alexandra | Chief Financial Officer | Jul 01 '26 | Sale | 123.58 | 11,430 | 1,412,519 | 85,533 | Jul 06 |
| Noci Darlene | Chief Development Officer | Jul 01 '26 | Option Exercise | 51.11 | 23,000 | 1,175,471 | 81,117 | Jul 06 |
| Noci Darlene | Chief Development Officer | Jun 29 '26 | Option Exercise | 27.85 | 5,500 | 153,175 | 63,617 | Jul 01 |
| Noci Darlene | Chief Development Officer | Jun 29 '26 | Sale | 123.51 | 5,500 | 679,305 | 58,117 | Jul 01 |
| Noci Darlene | Chief Development Officer | Jun 09 '26 | Option Exercise | 9.59 | 20,000 | 191,853 | 78,117 | Jun 11 |
| Noci Darlene | Chief Development Officer | Jun 09 '26 | Sale | 122.81 | 20,000 | 2,456,200 | 58,117 | Jun 11 |
| Porter James Richard | President and CEO | Jun 08 '26 | Option Exercise | 18.93 | 30,000 | 567,900 | 354,879 | Jun 10 |
| Porter James Richard | President and CEO | Jun 08 '26 | Sale | 88.53 | 30,000 | 2,656,005 | 324,879 | Jun 10 |
| Noci Darlene | Chief Development Officer | May 28 '26 | Option Exercise | 27.85 | 5,500 | 153,175 | 63,617 | Jun 01 |
| Noci Darlene | Chief Development Officer | May 28 '26 | Sale | 107.80 | 5,500 | 592,923 | 58,117 | Jun 01 |